Allopurinol News and Research

RSS
BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

Study finds anti-gout medication may reduce risk of colorectal cancer

Study finds anti-gout medication may reduce risk of colorectal cancer

Caffeine intake increases risk for recurrent gout attacks

Caffeine intake increases risk for recurrent gout attacks

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

FDA approves Krystexxa drug to treat gout

FDA approves Krystexxa drug to treat gout

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst second-quarter total revenues increase to $7.6 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Investment report on BioCryst Pharmaceuticals

Investment report on BioCryst Pharmaceuticals

European Congress of Nephrology unveils results of various clinical trials

European Congress of Nephrology unveils results of various clinical trials

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon study confirms potential utility of tranilast as uricosuric agent

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Allopurinol exhibits potential benefits for CKD patients

Allopurinol exhibits potential benefits for CKD patients